Perspective Therapeutics, Inc. (CATX)
3.13
+0.01
(+0.32%)
USD |
NYAM |
Sep 04, 16:00
3.145
+0.02
(+0.48%)
After-Hours: 20:00
Perspective Therapeutics SG&A Expense (TTM) : 29.46M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 29.46M |
| March 31, 2026 | 29.38M |
| December 31, 2025 | 30.23M |
| September 30, 2025 | 31.53M |
| June 30, 2025 | 30.77M |
| March 31, 2025 | 28.58M |
| December 31, 2024 | 26.61M |
| September 30, 2024 | 22.84M |
| June 30, 2024 | 20.85M |
| March 31, 2024 | 22.00M |
| September 30, 2023 | 18.36M |
| June 30, 2023 | 16.15M |
| March 31, 2023 | 13.49M |
| June 30, 2022 | 9.425M |
| March 31, 2022 | 9.16M |
| December 31, 2021 | 8.656M |
| September 30, 2021 | 8.084M |
| June 30, 2021 | 7.131M |
| March 31, 2021 | 7.098M |
| December 31, 2020 | 7.294M |
| September 30, 2020 | 7.283M |
| June 30, 2020 | 7.547M |
| March 31, 2020 | 7.291M |
| December 31, 2019 | 7.075M |
| September 30, 2019 | 7.141M |
| Date | Value |
|---|---|
| June 30, 2019 | 6.851M |
| March 31, 2019 | 7.404M |
| December 31, 2018 | 7.135M |
| September 30, 2018 | 6.991M |
| June 30, 2018 | 6.824M |
| March 31, 2018 | 6.634M |
| December 31, 2017 | 6.514M |
| September 30, 2017 | 6.231M |
| June 30, 2017 | 6.227M |
| March 31, 2017 | 5.702M |
| December 31, 2016 | 5.557M |
| September 30, 2016 | 5.560M |
| June 30, 2016 | 5.139M |
| March 31, 2016 | 4.772M |
| December 31, 2015 | 4.527M |
| September 30, 2015 | 3.989M |
| June 30, 2015 | 3.889M |
| March 31, 2015 | 3.722M |
| December 31, 2014 | 3.644M |
| September 30, 2014 | 3.642M |
| June 30, 2014 | 3.723M |
| March 31, 2014 | 3.720M |
| December 31, 2013 | 3.688M |
| September 30, 2013 | 3.640M |
| June 30, 2013 | 3.590M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Anika Therapeutics, Inc. | 52.67M |
| MiMedx Group, Inc. | 255.08M |
| ABVC BioPharma, Inc. | 6.400M |
| Enovis Corp. | 1.081B |
| Edwards Lifesciences Corp. | 2.201B |